Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Gardner A, Alvarez J, Genovese C, Snodgrass R, Kopparthy V, Erickson D, et al. Simplified detection of Epstein-Barr virus for diagnosis of endemic Burkitt lymphoma. Blood Adv. 2022;6(12):3650-3654.

Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer. 2022;128(4):654-664.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.

Church AJ, Corson LB, Kao P-, Imamovic-Tuco A, Reidy D, Doan D, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022;28(8):1581-1589.

Hao Y, Yang HS, Karbaschi M, Racine-Brzostek SE, Li P, Zuk R, et al. Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients. Biosens Bioelectron. 2022;209:114237.

Wulff RT, Qiu Y, Wu C, Calfee DP, Singh HK, Hatch I, et al. Laboratory Interventions to Eliminate Unnecessary Rapid COVID-19 Testing During a Reagent Shortage. Am J Clin Pathol. 2022;158(3):401-408.

Chen B-, Tyler JK, Sleckman BP. A Flow Cytometry-Based Method for Analyzing DNA End Resection in G0- and G1-Phase Mammalian Cells. Bio Protoc. 2022;12(10):e4413.

Nickeleit V, Singh HK, Davis VG, Seshan SV. Classifying Polyomavirus Nephropathy: The "Banff" Initiative. Transpl Int. 2022;35:10299.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541-553.